The correct option is (d) Meglitinide
Easy explanation: Meglitinide stimulates pancreatic cells to secrete more insulin. It should be taken just before meals, rapid onset, limited duration of action. Major adverse effects are hypoglycemia (low levels of blood sugar). Used in non-obese diabetics i.e. type 2 diabetes. Example: Repaglinide.